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ABSTRACT  
Objectives:  
Postoperative bleeding is still one of the most common complications of cardiac surgery. 
Antifibrinolytic agents successfully reduce bleeding, but there are controversies concerning adverse 
effects after their systemic use. By topical application of antifibrinolytic agents in pericardial cavity, 
most of these effects are avoided. We compared the effects of topically applied aprotinin, 
tranexamic acid and placebo on postoperative bleeding and transfusion requirements. 
Methods:  
In this single-center prospective, randomized, double-blind trial, 300 adult cardiac patients were 
randomized into 3 groups to receive one million IU of aprotinin (AP group), 2.5g of tranexamic acid 
(TA group) or placebo (PL group) topically before sternal closure. Groups were comparable with 
respect to all preoperative and intraoperative variables. Postoperative bleeding, transfusion 
requirements and hematologic parameters were evaluated.  
Results:  
Postoperative bleeding within first 12-hour period (AP group 433 ± 294 [350; 360] mL, TA group 
391 ± 255 [350; 305] mL, PL group 613 ± 505 [525; 348] mL), as well as cumulative blood loss 
within 24h (AP group 726 ± 432 [640; 525] mL, TA group 633 ± 343 [545; 335] mL, PL group 903 ± 
733 [800; 445] mL), showed statistically significant inter-group differences (both p<0.001).   
Bleeding rates values were significantly higher in placebo group compared to the groups treated 
with antifibrinolytic agents (AP and TA groups) concerning both variables. Although TA group 
showed the lowest values, no statistical differences between TA and AP groups were found. Inter-
group difference of blood product requirements was not statistically significant. 
Conclusions:  
Topical use of either tranexamic acid or aprotinin efficiently reduces postoperative bleeding. TA 
seems to be at least as potent as aprotinin, but potentially safer and with better cost-effectiveness 
ratio. 
KEYWORDS: 
cardiac surgery, postoperative bleeding, aprotinin, tranexamic acid 
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1. INTRODUCTION 
In time when systemic use of antifibrinolytic agents is highly controversial, with conflicting 
evidence of both benefits and adverse effects [1,2,3], topical application of these agents in 
pericardial cavity could provide alternative means to effectively reduce postoperative bleeding. 
Although the topical use of antifibrinolytic agents, such as aprotinin and tranexamic acid (TA), is 
not a novel method [4,5], it has not been widely accepted as a routine part of cardiac procedure. 
One of the main reasons is lack of evidence to support regular topical use of antifibrinolytic agents 
[6]. Only one randomized controlled trial by De Bonnis [7] demonstrated a clinically small benefit in 
favor of topical TA application over placebo in a group of low risk coronary patients. 
The aim of this study was to compare the effects of topically applied aprotinin with TA and 
placebo on postoperative bleeding and transfusion requirements. 
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2. MATERIAL AND METHODS 
After institutional approval was obtained, 300 patients scheduled for first-time elective cardiac 
procedure between May 2003 and April 2005 were enrolled in the study. The demographic data of 
our study groups is displayed in Table1. The study was carried out as a prospective, randomized, 
double-blind investigation with parallel groups.  
Exclusion criteria were as follows: procedures of thoracic aorta, redo procedures, active 
endocarditis, emergent procedures and known preexisting coagulation defects or abnormal platelet 
count.  
2.1. Pharmacological protocol 
After the enrollment, patients were randomized into three groups using random-number tables. 
The independent pharmacologist in hospital pharmacy prepared coded solutions with the study 
drugs or placebo and was not directly involved in the clinical treatment of randomized patients. 
Solutions contained one million IU of aprotinin (Trasylol; Bayer Pharma d.o.o., Ljubljana, Slovenia) 
in 250 mL of saline solution (AP group), 2.5 g of TA (Cyklokapron; Pharmacia AB, Stockholm, 
Sweden) in 250 mL of saline solution (TA group) or 250 mL of saline as placebo (PL group), 
without any other additives or preservatives. Identical bottles marked with a study number of patient 
were delivered to the operating theaters. Both the operation theater staff and that of the intensive 
care unit were blinded regarding the study drug and codes were disclosed at the end of the study. 
In all patients, antiaggregative therapy was discontinued for at least 5 days and anticoagulant 
therapy was continued up to 24 hours prior to surgery. There was no systemic appliance of either 
aprotinin or tranexamic acid in any patient. 
2.2. Surgical procedures and drug administration 
Different cardiac procedures were performed in this study (Table 2), reflecting the usual case-
mix performed at our Department. Patients with operations both with and without use of 
cardiopulmonary bypass (CPB) were included in study. 
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After thorough surgical hemostasis and before closure of the median sternotomy, study solution 
at room temperature was poured into the pericardial cavity and over the mediastinal tissues. After 
chest closure, study solution was suctioned out through chest tubes. After the patient was 
transferred to the intensive care unit (ICU), continuous suction (20 cm H2O) was applied, which was 
supplemented with periodic milking of the drains.  
2.3. Anesthetic protocol and cardiopulmonary bypass management 
Same anesthetic protocols were used for all patients. All patients were premedicated with 
morphine in the dose of 0.1 mg/kg IM (Morphine Merck; Merck KgaA, Darmstadt, Germany) one 
hour before surgery. Anesthesia was induced by 0.1 mg/kg IV midazolam (Dormicum; F. Hoffman-
La Roche Ltd., Basel, Switzerland), 5-7 g/kg IV fentanyl (Fentanyl; Janssen Pharmaceutica, 
Beerse, Belgium), and 0.1 mg/kg IV pancuronium-bromide (Pavulon; N.V. Organon, Oss, the 
Netherlands). After endotracheal intubation, the lungs were mechanically ventilated by positive 
pressure (tidal volume of 8 mL/kg and ventilatory frequency of 12/min) (Cato; Dräger, Lübeck, 
Germany). Tidal volume and respiratory rate were adjusted to maintain acid-base status and 
arterial CO2 pressure within physiological limits. Anesthesia was maintained with a nitrous-oxide 
mixture (60% oxygen and 40% nitrous oxide) and sevoflurane (Sevorane; Abbott Laboratories S.A., 
Abbott Park, IL, USA) in doses of 1.0-1.3 minimal alveolar concentration (MAC). Additional doses 
of pancuronium-bromide (0.1 mg/kg) were administered as required to maintain neuromuscular 
blockade during surgery. 
All cases which required CPB were performed in moderate hypothermia with cardiac arrest 
achieved with a single antegrade dose of blood cardioplegia followed by a continuous retrograde 
application of blood potassium cardioplegic solution. 
2.4. Anticoagulation during operation 
Heparin-sodium (Heparin; Belupo, Koprivnica, Croatia) was administered to achieve activated 
clotting time (ACT) of >480 seconds for patients undergoing the procedure with the use of CPB, 
and was checked every 20 minutes and re-administered according to the ACT values measured.  
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For patients undergoing the procedure without CPB (off-pump), heparin was administered to 
achieve ACT time of at least 200 seconds.  
In patients undergoing coronary revascularization (both on- and off-pump) heparin was 
administered at the end of LIMA takedown. In valvular patients heparin was administered upon 
placing the cannulation stitches. 
At the end of the procedure heparin was fully reversed with protamine-hydrochloridum 
(Protamin ICN; ICN Pharmaceuticals, Birsfelden, Switzerland) in all patients. In patients undergoing 
surgery with the use of CPB heparin reversal started upon the removal of the venous cannula, and 
in patients undergoing off-pump surgery upon the completion of the last anastomosis.  
2.5. Transfusion policy 
Criteria for transfusion of packed red blood cells were as follows: hematocrit value less than 
30% and haemoglobin value less than 90 g/dL accompanied by signs or symptoms of hypovolemia 
after CPB and during the ICU stay. The criterion for transfusion of fresh frozen plasma was a 
prothrombin time greater than 1.5 (international normalized ratio) with excessive bleeding, defined 
as greater than 200 mL/h for 2 consecutive hours. The criterion for transfusion of platelet 
concentrates was a platelet count less than 50,000/mm3 with excessive bleeding (>200 mL/h for 2 
consecutive hours). Surgical re-exploration was performed if bleeding in the first 2 hours was 
greater than 300 mL/h or greater than 200 mL/h for 4 consecutive hours with normal coagulation 
parameters.  
2.6. Data collection and laboratory analysis  
Postoperatively, blood loss from the mediastinal chest tubes was recorded at 12 and 24 hours 
from the time patient arrived in the ICU. Blood product transfusions were documented for the entire 
postoperative hospital stay. All clinical data was harvested from CardioBase, custom-made 
database of cardiac patients that is routinely used at our Department.  
Plasma concentration of hemoglobin, hematocrit level, platelet count, prothrombin time, 
activated partial thromboplastin time (aPTT) and fibrinogen levels were measured before operation 
and after patient's arrival in the ICU. 
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2.7. Statistical analysis 
Continuous variables are presented as mean ± standard deviation and, for variables with a 
skew distribution, additionally median with interquartile range was given. 
Test of normality (Kolmogorov-Smirnov statistic, with a Lilliefors significance level) has been 
performed for all continuous variables. For variables with a normal distribution (pre- and 
postoperative hematologic characteristics), statistical comparison of groups was carried out using 
analysis of variance (ANOVA) and, for significant inter-group differences, Sidak's and Dunnett's 
post hoc tests were applied to locate the between-group differences. For variables with a skew 
distribution (all bleeding results and transfusion requirements), Kruskal-Wallis test was used and, 
for statistically significant differences, Mann-Whitney test with Bonferoroni correction was used for 
post-hoc comparisons.  
The χ2 test or Fisher exact test was used to compare categoric data.  
All statistical tests were evaluated at significant level of 0.05. Statistical analysis was performed 
using SPSS, version 11.0 (SPSS, Inc., Chicago, IL, USA)  
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3. RESULTS 
Six patients were withdrawn from the study due to the postoperative reopening for bleeding 
where an evident surgical source of bleeding was discovered. One patient dropped-out from the 
study due to the technical mistake. A total of 293 patients were assessed in the study: 100 patients 
in AP group, 97 in TA group and 96 in PL group. 
The three groups were comparable with regard to age, sex, diabetes and EuroSCORE (both 
additive and logistic), as shown in Table 1. There were no inter-group differences concerning both 
CPB use (p=0.27) and percentage of isolated coronary surgery (p=0.29). Laboratory analyses 
showed not differences between the three groups, both pre- (Table ) and postoperatively (Table ). 
From 293 enrolled patients, 6 of them (2%) died: 2 in AP group, 1 in TA group, 3 in PL group 
(p=0.59). Three patients died of cardiac reasons (perioperative myocardial infarction - 2, malignant 
arrhythmia - 1) and 3 from non-cardiac reasons (sepsis - 2, stroke - 1).   
3.1. Postoperative blood loss 
Postoperative blood loss for first and second 12- hour periods, as well as cumulative blood loss 
at 24h is presented in Figure 1 (a-c). Postoperative bleeding within first 12-hour period (AP group 
433 ± 294 [350; 360] mL, TA group 391 ± 255 [350; 305] mL, PL group 613 ± 505 [525; 348] mL), 
as well as cumulative blood loss within 24h (AP group 726 ± 432 [640; 525] mL, TA group 633 ± 
343 [545; 335] mL, PL group 903 ± 733 [800; 445] mL), showed statistically significant inter-group 
differences (both p<0.001). In both cases, placebo group bleeding was significantly higher than 
bleeding in groups treated with antifibrinolytic agents. Although TA group showed the lowest 
values, no statistical differences were found between TA and AP groups. Decrease of mean 
cumulative blood loss at 24h was about 30% (270 mL) in TA group, and 20% (169 mL) in AP 
group, when compared to placebo. There was no inter-group difference in blood loss during second 
12-hour period (p=0.46; AP group 293 ± 228 [225; 223] mL, TA group 242 ± 144 [200; 140] mL, PL 
group 290 ± 275 [250; 140] mL). 
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3.2. Transfusion requirements 
In AP group, 53 patients (53%) received packed red blood cells, in TA group 51 (53%) and in 
PL group 51 (53%), with no differences between groups (p=0.99). Total amount of packed red 
blood cells transfused was highest in PL group (AP group 596 ± 803 [300; 755] mL, TA group 423 ± 
483 [320; 690] mL, PL group 647 ± 1137 [370; 805] mL), but no significant inter-group differences 
(p=0.44) were found. Results are presented in Figure 1 (d) 
3.3. Subgroups analyses 
Statistical analysis of 2 subgroups of our study population has been performed. CPB subgroup 
included patients operated only with CPB support and OPCAB subgroup included patients 
operated without using CPB. 
Results of CPB subgroup are displayed in Table . Again, significant inter-group differences 
were observed, concerning postoperative blood loss during first 12-hour period and cumulative 
blood loss within 24 hours. Posthoc analyses revealed that PL group differs significantly from both 
AP and TA groups, with no differences between later two. Decrease of mean cumulative blood loss 
at 24h was 37% (308 mL) in TA group, and 20% (163 mL) in AP group, when compared to placebo. 
Results of OPCAB subgroup are displayed in Table . In this subgroup, inter-group difference 
was significant concerning only postoperative bleeding during first 12-hour period. Posthoc 
analyses revealed significant difference only between AP and PL group, with reduction of bleeding 
of 170ml (28%) in AP group. 
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4. DISCUSSION 
 This study reveals favorable effect of topically applied antifibrinolytic agents after cardiac 
operation: both aprotinin and TA efficiently reduce blood loss in first 12 hours in a large and 
heterogeneous group of cardiac patients. Cumulative blood loss at 24h after surgery was 
significantly lower compared to placebo - by 20% in AP group and 30% in TA group. Although 
evident, the difference between two antifibrinolytic agents in favor of TA was not statistically 
significant. The fact that there is no difference between groups in blood loss during second 12-h 
period is anticipated and is in accordance with results from De Bonis and colleagues, who 
demonstrated that hemostatic effect of 1% solution of TA lasted for 3-4 hours [7]. 
First study of topical application of antifibrinolytic agents was reported back in 1993, when Tatar 
and colleagues demonstrated evident reduction of both postoperative bleeding and the need for 
transfusion after topical use of aprotinin in 25 coronary patients [4]. Their results were further 
verified by double-blind, randomized trial on 100 patients undergoing cardiac operations with CPB 
published in 1995 by O'Regan and his group [5]. Cicek et al. [8] showed in 1995 that topically 
applied aprotinin could not be detected in blood and proposed that it locally relieves fibrinolytic 
state present in thoracic cavity after cardiopulmonary bypass. The same author year later raised a 
concern that aprotinin application in thoracic cavity may enhance postoperative mediastinal 
adhesion formation through its antifibrinolytic effects [9] 
De Bonis and colleagues [7] published in 2000 a double blinded controlled trial with 40 patients 
undergoing primary CABG with 25% reduction of bleeding after 24 hours in group treated with TA, 
but with no reduction in allogenic transfusions. No systemic absorption of TA was noted. Proposed 
action of TA is a stabilization of formed cloths by removal of plasminogen from their fibrin surface 
and therefore inhibition of plasmin-induced resolution of fibrin 
Our intention was to compare effects of both antifibrinolytic agents in larger RCT and to find out 
if their effects justify regular use in cardiac surgery. Decision to include both patients with and 
without CPB use in our study reflects regular high percent of off-pump surgery at our department. 
The potential influence of CPB on results is neutralized by the fact that there are no statistical 
differences between groups concerning CPB use. Patients at higher risk for postoperative bleeding, 
Baric et al.   
Topical Use of Antifibrinolytic Agents 11 
 
 
such as aortic dissections or reoperations, were excluded from the study because of expected 
systemic applications of aprotinin. 
Although the amount of transfused blood products was almost 250 mL lower in TA group 
compared to placebo, our study failed to show statistically significant decrease of transfusion 
requirements. Despite reduction of postoperative bleeding, there was still a relatively high 
percentage of patients receiving transfusions. This fact is most probably due to flexible adherence 
to transfusion criteria. Several other studies of either topical or systemic application of different 
antifibrinolytic agents also failed to show differences in blood products transfusions [7,10,11,12]. 
Additional statistical analysis showed the same results in a subgroup of patients operated with 
use of CPB. On the other hand, in the subgroup of patients operated without use of CPB (OPCAB 
subgroup), significant difference was shown only concerning bleeding during first 12-hour periods, 
with only AP group being considerably lower then placebo! This result suggests that aprotinin is 
more potent then tranexamic acid when no CPB is being used. However, these results must be 
interpreted with caution, because of the smaller sample sizes of mentioned subgroups. 
We also have to mention impressive differences regarding the cost of the 2 drugs: at our 
institution the aprotinin protocol costs round 71€ per patient, whereas the TA application costs only 
23€ per patient.  
Based on the results of this double blinded randomized trial, we can conclude that topical 
application of both aprotinin and TA efficiently reduces postoperative bleeding. TA seems to be at 
least as potent as aprotinin, but potentially safer and with better cost-effectiveness ratio.  
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5. TABLES 
Table 1. Baseline characteristics of study groups.  
 
  
AP group 
(n=100) 
TA group 
(n=97) 
PL group 
(n=96) P-value 
Age (years) 61.1 ± 9.3 [63; 14] 61.2 ± 10.7 [63; 16] 61.2 ± 10.3 [62.5, 15] 0,99 
Female patients  27 (27%) 20 (20.6%) 26 (27.1%) 0,49 
Diabetes mellitus 19 (19%) 18 (18.6%) 14 (14.6%) 0,58 
CPB used 49 (49%) 52 (53.6%) 58 (60.4%) 0,27 
Coronary surgery only 66 (66%) 72 (74.2%) 62 (64.6%) 0,30 
EuroScore (additive) 3.4 ± 2.2 [3; 3] 3.3 ± 2.2 [3; 3] 3.7 ± 2.4 [3; 3] 0,47 
EuroScore (logistic, %) 3.0 ± 2.2 [2.3; 2.5] 3.0 ± 2.4 [2.3; 1.2] 3.7 ± 4.8 [2.3; 2.8] 0,22 
 
 
Results are presented as n (%) or mean ± SD [median; interquartile range]. 
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Table 2. Surgical procedures performed, according to the study groups  
 
  
AP group 
(n=100) 
TA group 
(n=97) 
PL group 
(n=96) 
Total % 
OPCAB 50 46 38 134 45,7 
CABG 16 26 24 66 22,5 
AV 11 16 8 35 11,9 
CABG & AV 6 4 7 17 5,8 
MV 5 2 3 10 3,4 
CABG & other 3  4 7 2,4 
other 5 1 1 7 2,4 
CABG & MV 1 1 3 5 1,7 
MV & other 2  2 4 1,4 
AV & MV   3 3 1,0 
AV & other 1 1  2 0,7 
AV & MV & other   1 1 0,3 
CABG & AV & MV   1 1 0,3 
CABG & MV & other   1 1 0,3 
 
OPCAB – off pump coronary artery bypass, CABG – coronary artery bypass grafting, AV – 
aortic valve procedure, MV – mitral valve procedure, other – other cardiac procedure 
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Table 3. Preoperative hematologic characteristics of study groups.  
 
  
AP group 
(n=100) 
TA group 
(n=97) 
PL group 
(n=96) 
P-value 
Hematocrit (%) 40.7 ± 5 41.3 ± 4.1 40.9 ± 5.1 0.77 
Hemoglobin (g/dL) 140 ± 16 156 ± 143 139 ± 19 0.35 
Platelet count (109/L) 195 ± 49 214 ± 54 205 ± 67 0.14 
INR 1.050 ± 0.109 1.039 ± 0.102 1.098 ± 0.453 0.39 
aPTT (sec.) 32.8 ± 4.8 32.7 ± 4.9 32.7 ± 5 0.98 
Fibrinogen (g/L) 3.766 ± 1.038 3.948 ± 1.117 3.94 ± 1.148 0.52 
 
Results are presented as mean ± SD (all variables show normal distribution). 
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Table 4. Postoperative hematologic characteristics of study groups 
 
  
AP group 
(n=100) 
TA group 
(n=97) 
PL group 
(n=96) 
P-value 
Hematocrit (%) 32.2 ± 3.4 32.3 ± 3.2 32.6 ± 3.2 0.74 
Hemoglobin (g/dL) 112 ± 13 112 ± 13 113 ± 13 0.93 
Platelet count (109/L) 128 ± 46 136 ± 53 134 ± 47 0.52 
INR 1.710 ± 0.869 1.642 ± 0.623 1.822 ± 0.775 0.69 
aPTT (sec.) 52.1 ± 24.8 75 ± 61.5 42.2 ± 15.9 0.21 
Fibrinogen (g/L) 3.086 ± 1.478 3.883 ± 0.512 3.4 ± 1.679 0.59 
 
Results are presented as mean ± SD (all variables show normal distribution). 
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Table 5. CPB subgroup results 
 
 
 
AP group 
(n=51) 
TA group 
(n=51) 
PL group 
(n=58) 
 
  mean SD median 
interqartile 
range mean SD median 
interqartile 
range mean SD median 
interqartile 
range P-value 
Bleeding 0-12h (ml) 411 323 300 310 311 179 260 208 552 297 500 320 <0.001 
Bleeding 12-24h (ml) 259 201 180 220 214 97 200 93 281 236 250 150 0.17 
Bleeding 0-24h (ml) 670 441 600 340 525 222 460 235 833 440 800 410 <0.001 
PRBC transfusion (ml) 853 969 600 1385 476 479 365 698 782 1403 380 960 0.51 
Postoperative hospital stay (days) 12.3 9.6 10.0 5.0 10.0 2.8 9.5 4.3 12.8 8.1 10.0 5.0 0.19 
 
 
 
Table 6. OPCAB subgroup results 
 
 
AP group 
(n=49) 
TA group 
(n=48) 
PL group 
(n=38) 
 
  mean SD median 
interqartile 
range mean SD median 
interq. 
range mean SD median 
interq. 
range P-value 
Bleeding 0-12h (ml) 435 257 370 360 481 312 400 428 605 344 550 310 0.042 
Bleeding 12-24h (ml) 336 239 280 243 291 196 230 175 251 131 230 110 0.69 
Bleeding 0-24h (ml) 771 402 685 513 772 446 690 545 856 423 800 415 0.35 
PRBC transfusion (ml) 309 451 135 540 321 437 0 553 391 365 350 690 0.20 
Postoperative hospital stay (days) 9.7 4.2 9.0 4.0 8.9 1.9 8.0 2.3 11.7 6.1 9.0 5.0 0.22 
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6. FIGURES 
Figure 1. Boxplots representing: blood loss during the first 12-hour period (a), the second 12-hour 
period (b), cumulative blood loss at 24h (c) and packet red blood cells transfusions (d).  
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